Systemic lupus erythematosus

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R A Furie, G Leon, M Thomas, M A Petri, A D Chu, C Hislop, R S Martin, M A Scheinberg

Annals of the Rheumatic Diseases Sep 2015, 74 (9) 1667-1675; DOI: 10.1136/annrheumdis-2013-205144
Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus
I E M Bultink, T Teerlink, J A Heijst, B A C Dijkmans, A E Voskuyl

Annals of the Rheumatic Diseases Sep 2005, 64 (9) 1362-1365; DOI: 10.1136/ard.2005.036137
Lupus thrombocytopenia: clinical implications and prognostic significance
P D Ziakas, S Giannouli, E Zintzaras, A G Tzioufas, M Voulgarelis

Annals of the Rheumatic Diseases Sep 2005, 64 (9) 1366-1369; DOI: 10.1136/ard.2004.033100
Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients
Ryan Webb, Jennifer A Kelly, Emily C Somers, Travis Hughes, Kenneth M Kaufman, Elena Sanchez, Swapan K Nath, Gail Bruner, Marta E Alarcón-Riquelme, Gary S Gilkeson, Diane L Kamen, Bruce C Richardson, John B Harley, Amr H Sawalha

Annals of the Rheumatic Diseases Jan 2011, 70 (1) 151-156; DOI: 10.1136/ard.2010.141697
Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus
D M Chang, S J Chu, H C Chen, S Y Kuo, J H Lai

Annals of the Rheumatic Diseases Dec 2004, 63 (12) 1623-1626; DOI: 10.1136/ard.2003.016576
Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZB×NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies
Z M Sthoeger, H Zinger, E Mozes

Annals of the Rheumatic Diseases Apr 2003, 62 (4) 341-346; DOI: 10.1136/ard.62.4.341
Expansion of myelin autoreactive CD8+ T lymphocytes in patients with neuropsychiatric systemic lupus erythematosus
Cécile Contin-Bordes, Estibaliz Lazaro, Christophe Richez, Clément Jacquemin, Olivier Caubet, Isabelle Douchet, Jean-François Viallard, Jean-François Moreau, Jean-Luc Pellegrin, Patrick Blanco

Annals of the Rheumatic Diseases May 2011, 70 (5) 868-871; DOI: 10.1136/ard.2010.140012
A6.17 FCGR2A association with susceptibility to autoimmune and inflammatory diseases
JI Robinson, JC Taylor, E Foy, T Vyse, R Cooper, H Chinoy, J Lamb, A Barton, J Martin, AH Sawalha, AG Wilson, JH Barrett, AW Morgan

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A54-A55; DOI: 10.1136/annrheumdis-2016-209124.129
A2.01 The expansion of CD25^highIL-10^highFOXP3^high B regulatory cells is in association with sle disease activity
E Toubi, Z Vadasz

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A15; DOI: 10.1136/annrheumdis-2016-209124.36
Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up
G Castellino, M Govoni, M Padovan, P Colamussi, M Borrelli, F Trotta

Annals of the Rheumatic Diseases Jul 2005, 64 (7) 1022-1027; DOI: 10.1136/ard.2004.026773

Main menu

Systemic lupus erythematosus

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Systemic lupus erythematosus

Pages